Thermo Fisher Scientific has unveiled a new set of solutions to support adeno-associated viral (AAV) manufacturing. A new media panel, gene kit and advanced purification resins help reduce manufacturing costs while increasing the viability of gene therapies as treatment options for patients.   AAV is a non-pathogenic virus with the ability to infect cells at various stages of growth, and has become a preferred “viral vector” for delivering gene therapies. However, scalability of AAV ...